Cargando…
Long-Term Efficacy of Neoadjuvant Concurrent Chemoradiotherapy for Potentially Resectable Advanced Siewert Type II and III Adenocarcinomas of the Esophagogastric Junction
BACKGROUND: Reports have shown that neoadjuvant concurrent chemoradiotherapy (nCRT) increases the R0 resection rate for patients with Siewert type II or III adenocarcinoma of the gastroesophageal junction (AEG). However, the long-term efficacy of nCRT for AEG patients remains unclear. In this multic...
Autores principales: | Tian, Yuan, Wang, Jun, Qiao, Xueying, Zhang, Jun, Li, Yong, Fan, Liqiao, Zhang, Zhidong, Zhao, Xuefeng, Tan, Bibo, Wang, Dong, Yang, Peigang, Zhao, Qun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8632141/ https://www.ncbi.nlm.nih.gov/pubmed/34858829 http://dx.doi.org/10.3389/fonc.2021.756440 |
Ejemplares similares
-
Concurrent Neoadjuvant Chemoradiotherapy for Siewert II and III Adenocarcinoma at Gastroesophageal Junction
por: Zhao, Qun, et al.
Publicado: (2015) -
Efficacy of Neoadjuvant Chemotherapy DOX and XELOX Regimens for Patients with Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
por: Tian, Yuan, et al.
Publicado: (2021) -
Nomograms for Predicting Disease-Free Survival in Patients With Siewert Type II/III Adenocarcinoma of the Esophagogastric Junction Receiving Neoadjuvant Therapy and Radical Surgery
por: Guo, Zhenjiang, et al.
Publicado: (2022) -
The optimal extent of lymph node dissection for adenocarcinoma of the esophagogastric junction differs between Siewert type II and Siewert type III patients
por: Goto, Hironobu, et al.
Publicado: (2014) -
Neoadjuvant chemoradiotherapy improves survival in locally advanced adenocarcinoma of esophagogastric junction compared with neoadjuvant chemotherapy: a propensity score matching analysis
por: Li, Jing, et al.
Publicado: (2021)